Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy

Journal of Human Hypertension

Volumn 18, Issue 6, 2004, Pages 375-380

  Fossum, Eigel ^a   Olsen, M H ^b   Hoieggen A ^a   Wachtell, K ^b   Reims, H M ^a   Ibsen, H ^b   Julius, S ^c   Kjeldsen, S E ^a,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Dept Clin Physiol/Nuclear Med ^*  (Denmark)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin receptor blocker; Beta blocker; Hypertension; LIFE; Sympathetic activity

Indexed keywords

ADRENALIN; ATENOLOL; CATECHOLAMINE; LOSARTAN; NORADRENALIN; PLACEBO;

ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NORADRENALIN BLOOD LEVEL; PATHOGENESIS; REST; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CATECHOLAMINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; TIME FACTORS;

EID: 2942733509     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001712     Document Type: Article

References (28)

1. Lewington S et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
2. Ezzati M et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-1360.
3. DeQuattro V, Chan S. Raised plasma-catecholamines in some patients with primary hypertension. Lancet 1972; 1: 806-809.
4. Egan B et al. Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension. J Clin Invest 1987; 80: 812-817.
5. Eliasson K, Hjemdahl P, Kahan T. Circulatory and sympatho-adrenal responses to stress in borderline and established hypertension. J Hypertens 1983; 1: 131-139.
6. Hjemdahl P. Plasma catecholamines as markers for sympatho-adrenal activity in human primary hypertension. Pharmacol Toxicol 1988; 63(Suppl 1): 27-31.
7. Julius S, Schork N, Schork A. Sympathetic hyperactivity in early stages of hypertension: the Ann Arbor data set. J Cardiovasc Pharmacol 1988; 12(Suppl 3): S121-S129.
8. Kjeldsen SE, Schork NJ, Leren P, Eide IK. Arterial plasma norepinephrine correlates to blood pressure in middle-aged men with sustained essential hypertension. Am Heart J 1989; 118: 775-781.
9. Dahlöf B et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
10. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
11. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967-1975.
12. Kjeldsen SE, Westheim AS, Os I. INSIGHT and NORDIL. International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment. Nordic Diltiazem Study. Lancet 2000; 356: 1929-1930.
13. Dahlöf B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
14. Olsen MH et al. Relative influence of insulin resistance versus blood pressure on vascular changes in long-standing hypertension. ICARUS, a LIFE sub study. Insulin Carotids US Scandinavia. J Hypertens 2000; 18: 75-81.
15. Olsen MH et al. A possible link between endothelial dysfunction and insulin resistance in hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Blood Press 2000; 9(2-3): 132-139.
16. Appel E et al. Determination of plasma catecholamines by means of radioenzymatic labelling and high pressure liquid chromatographic separation. Naunyn Schmiedebergs Arch Pharmacol 1981; 315: 233-239.
17. Best JD, Halter JB. Release and clearance rates of epinephrine in man: importance of arterial measurements. J Clin Endocrinol Metab 1982; 55: 263-268.
18. Esler M. Assessment of sympathetic nervous function in humans from noradrenaline plasma kinetics. Clin Sci 1982; 62: 247-254.
19. Gullestad L et al. Effect of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise. Cardiovasc Drugs Ther 1989; 3: 63-71.
20. Reid IA. Interactions between ANG ll, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262: E763-E778.
21. Ye S, Zhong H, Duong VN, Campese VM. Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension 2002; 39: 1101-1106.
22. Rodriguez-Garcia JL et al. Changes in plasma norepinephrine and endothelin levels and metabolic profile after AT1-receptor blockade in human hypertension. Am J Cordiol 2000; 85: 1147-1150.
23. Houghton AR, Harrison M, Cowley AJ. Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly. Eur J Heart Fail 1999; 1: 385-393.
24. Grossman E et al. Hemodynamic and humoral effects of the angiotensin ll antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041-1044.
25. Worck RH, Ibsen H, Frandsen E, Dige-Petersen H. AT1 receptor blockade and the sympathoadrenal response to insulin-induced hypoglycemia in humans. Am J Physiol 1997; 272: E415-E421.
26. Rowe JW et al. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219-225.
27. Seljeflot I et al. Effect of angiotensin ll receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996; 27: 1299-1304.
28. Moan A et al. The glucose clamp procedure activates the sympathetic nervous system even in the absence of hyperinsulinemia. J Clin Endocrinol Metab 1995; 80: 3151-3154.